P2.07. Association between OS and Subsequent ICI in Control Arm Patients of First Line ICI-based RCTs of Advanced/Metastatic NSCLC: FDA Analysis - PDF(Abstract)
Back to course
Pdf Summary
Asset Subtitle
Oladimeji Akinboro
Meta Tag
Speaker Oladimeji Akinboro
Topic Metastatic NSCLC: Immunotherapy - Retrospective
retrospective analysis
U.S. Food and Drug Administration
overall survival
immune checkpoint inhibitors
metastatic non-small cell lung cancer
randomized controlled trials
chemotherapy control arms
on-study crossover
patient-level data
Powered By